MARKET

OCUP

OCUP

Ocuphire Pharma Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.30
+0.49
+6.27%
Opening 11:14 01/20 EST
OPEN
7.99
PREV CLOSE
7.81
HIGH
9.47
LOW
7.82
VOLUME
248.36K
TURNOVER
--
52 WEEK HIGH
17.04
52 WEEK LOW
3.680
MARKET CAP
89.99M
P/E (TTM)
-1.3244
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Ocuphire announces peer-reviewed publication of Phase 2 results for Nyxol
Ocuphire Pharma (OCUP) announced that results from its ORION-1 (NCT03960866) Phase 2 clinical trial evaluating the safety and efficacy of Nyxol® in glaucoma and presbyopia have been published in the peer-reviewed, open access journal,
Seekingalpha · 1h ago
BRIEF-Ocuphire Announces Publication Of ORION-1 Phase 2 Results For Nyxol In Clinical Ophthalmology And Presentation At The January OIS Presbyopia Innovation Showcase
reuters.com · 4h ago
Ocuphire concludes enrollment in late-stage trial of Nyxol for dilated pupil condition
Clinical-stage ophthalmic biopharmaceutical company Ocuphire Pharma ([[OCUP]] -1.5%) has completed enrollment in its MIRA-2 Phase 3 study evaluating the safety and efficacy of Nyxol to reverse pharmacologically-induced mydriasis ((dilation of the pupil of the
Seekingalpha · 01/06 15:07
Ocuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol(R) for Reversal of Mydriasis
Nyxol has Potential to be a New Treatment Option for Reversal of Pharmacologically-Induced Pupil Dilation
GlobeNewswire · 01/06 12:00
Ocuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis
Nyxol has Potential to be a New Treatment Option for Reversal of Pharmacologically-Induced Pupil DilationTop-Line Data for MIRA-2 Expected by End of Q1 2021FARMINGTON HILLS, Mich., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a c...
GlobeNewswire · 01/06 12:00
Ocuphire Pharma launches late-stage study of Nyxol in night vision disturbances
Ocuphire Pharma (OCUP) has initiated patient recruitment and screening in late December for its LYNX-1 Phase 3 registration study evaluating the safety and efficacy of Nyxol in night vision disturbances ((NVD))
Seekingalpha · 01/05 12:59
Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbances
Nyxol is in Late Stage Clinical Development for A New Ophthalmic Indication
GlobeNewswire · 01/05 12:00
Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbances
GlobeNewswire · 01/05 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OCUP. Analyze the recent business situations of Ocuphire Pharma Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OCUP stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 24
Institutional Holdings: 93.37K
% Owned: 0.86%
Shares Outstanding: 10.84M
TypeInstitutionsShares
Increased
3
13.06K
New
6
-184
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.27%
Pharmaceuticals & Medical Research
-0.21%
Key Executives
Chairman/Director
Cam Gallagher
President/Chief Executive Officer/Vice Chairman/Treasurer/Director
Mina Sooch
Chief Accounting Officer/Vice President - Finance
Amy Rabourn
Director
Gil Price
Lead Director/Independent Director
Sean Ainsworth
Director
Susan Benton
Director
James Manuso
Director
Alan Meyer
Independent Director
Richard Rodgers
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About OCUP
Ocuphire Pharma, Inc. is a clinical-stage ophthalmic biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of eye disorders. Its pipeline includes two small-molecule product candidates targeting front and back of the eye indications. The Company’s lead product candidate, Nyxol Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size. Nyxol is being developed for several indications, including dim light or night vision disturbances (NVD), reversal pharmacologically-induced mydriasis (RM), and presbyopia. Its second product candidate, APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Ocuphire Pharma Inc stock information, including NASDAQ:OCUP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OCUP stock methods without spending real money on the virtual paper trading platform.